Nailfold capillary abnormalities in a patient with stiff-person syndrome: Potential novel window into pathogenesis

Abstract

Keywords

autoimmunity GAD65 microcirculation nailfold videocapillaroscopy stiff-person syndrome

Get full access to this article

View all access options for this article.

References

Crane

Sillau

Dreher

, et al. Population-based study of the epidemiology of stiff person syndrome in a large Colorado-based health system. Neurology 2024; 103: e210078.

Dalakas

. Stiff-person syndrome and GAD antibody-spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies. Neurotherapeutics 2022; 19: 832–847.

Tsiortou

Alexopoulos

Dalakas

. GAD antibody-spectrum disorders: Progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. Ther Adv Neurol Disord 2021; 14: 17562864211003486.

Smith

Herrick

Ingegnoli

, et al. Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud’s phenomenon and systemic sclerosis. Autoimmun Rev 2020; 19: 102458.

Lledó-Ibáñez

Sáez Comet

Freire

, et al. CAPI-Detect: Machine learning in capillaroscopy reveals new variables influencing diagnosis. Rheumatology (Oxford) 2025; 64: 3667–3675.

Smith

Vanhaecke

Herrick

, et al. Fast track algorithm: How to differentiate a “scleroderma pattern” from a “non-scleroderma pattern”. Autoimmun Rev 2019; 18: 102394.

Ingegnoli

Gualtierotti

Lubatti

, et al. Nailfold capillary patterns in healthy subjects: A real issue in capillaroscopy. Microvasc Res 2013; 90: 90–95.

Gorasiya

Mehta

Prakashey

Dave

. Nailfold capillaroscopy of healthy individuals—An observational study. Indian Dermatol Online J 2022; 13: 600–605.

Hysa

Pizzorni

Gotelli

, et al. Microvascular damage in autoimmune connective tissue diseases: A capillaroscopic analysis from 20 years of experience. RMD Open 2023; 9: e003071.

10.

Towns

Pietropaolo

. GAD65 autoantibodies and its role as biomarker of Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA). Drugs Future 2011; 36: 847.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

11.87 MB

0.00 MB